

PCT

(Original in Electronic Form)

VIII-2-1	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name	In relation to this international application NOVARTIS AG is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-1 (iv)		an assignment from GOLOSOV, Andrei Alexandrovich to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., dated 04 June 2024 (04.06.2024)
VIII-2-1 (iv)		an assignment from NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. to NOVARTIS AG, dated 16 July 2024 (16.07.2024)
VIII-2-1 (iv)		an assignment from CLEMENTE, Gonçalo dos Santos to NOVARTIS PHARMA AG, dated 05 June 2024 (05.06.2024)
VIII-2-1 (iv)		an assignment from FISCHER, Matteo to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from GROSCHE, Philipp to NOVARTIS PHARMA AG, dated 06 June 2024 (06.06.2024)
VIII-2-1 (iv)		an assignment from HOLZER, Philipp to NOVARTIS PHARMA AG, dated 06 June 2024 (06.06.2024)
VIII-2-1 (iv)		an assignment from KARPOV, Alexei to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from LACAUD-BAUMLIN, Marion to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from LEDER, Lukas to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from MALO, Rafael Bermeo to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from MARZINZIK, Andreas to NOVARTIS PHARMA AG, dated 05 June 2024 (05.06.2024)
VIII-2-1 (iv)		an assignment from MUNSCH, Charlie to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from RESCHKE, Markus Oliver to NOVARTIS PHARMA AG, dated 06 June 2024 (06.06.2024)
VIII-2-1 (iv)		an assignment from SELLNER, Holger to NOVARTIS PHARMA AG, dated 05 June 2024 (05.06.2024)
VIII-2-1 (iv)		an assignment from STACHYRA, Therese-Marie to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from NOVARTIS PHARMA AG to NOVARTIS AG, dated 06 June 2024 (06.06.2024)
VIII-2-1 (iv)		an assignment from EHARA, Takeru to PEPTIDREAM INC. (ALSO KNOWN AS PEPTIDREAM K.K.), dated 19 June 2024 (19.06.2024)
VIII-2-1 (iv)		an assignment from MIZUKOSHI, Yoshihide to PEPTIDREAM INC. (ALSO KNOWN AS PEPTIDREAM K.K.), dated 19 June 2024 (19.06.2024)

PCT

(Original in Electronic Form)

VIII-2-1 (iv)		an assignment from PEPTIDREAM INC. (ALSO KNOWN AS PEPTIDREAM K.K.) to NOVARTIS PHARMA AG, dated 24 June 2024 (24.06.2024)
VIII-2-1 (iv)		an assignment from NOVARTIS PHARMA AG to NOVARTIS AG, dated 01 August 2024 (01.08.2024)
VIII-2-1 (iv)		an assignment from BONGARZONE, Salvatore to ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L., dated 24 July 2024 (24.07.2024)
VIII-2-1 (iv)		an assignment from CAMPORESE, Davide to ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L., dated 24 July 2024 (24.07.2024)
VIII-2-1 (iv)		an assignment from ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. to NOVARTIS AG, dated 01 August 2024 (01.08.2024)
VIII-2-1 (iv)		an assignment from GOLOSOV, Andrei Alexandrovich to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., dated 04 June 2024 (04.06.2024)
VIII-2-1 (iv)		an assignment from NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. to NOVARTIS AG, dated 16 July 2024 (16.07.2024)
VIII-2-1 (iv)		an assignment from CLEMENTE, Gonçalo dos Santos to NOVARTIS PHARMA AG, dated 05 June 2024 (05.06.2024)
VIII-2-1 (iv)		an assignment from FISCHER, Matteo to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from GROSCHE, Philipp to NOVARTIS PHARMA AG, dated 06 June 2024 (06.06.2024)
VIII-2-1 (iv)		an assignment from HOLZER, Philipp to NOVARTIS PHARMA AG, dated 06 June 2024 (06.06.2024)
VIII-2-1 (iv)		an assignment from KARPOV, Alexei to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from LACAUD-BAUMLIN, Marion to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from LEDER, Lukas to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from MALO, Rafael Bermeo to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from MARZINZIK, Andreas to NOVARTIS PHARMA AG, dated 05 June 2024 (05.06.2024)
VIII-2-1 (iv)		an assignment from MUNSCH, Charlie to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from RESCHKE, Markus Oliver to NOVARTIS PHARMA AG, dated 06 June 2024 (06.06.2024)
VIII-2-1 (iv)		an assignment from SELLNER, Holger to NOVARTIS PHARMA AG, dated 05 June 2024 (05.06.2024)
VIII-2-1 (iv)		an assignment from STACHYRA, Therese-Marie to NOVARTIS PHARMA AG, dated 03 June 2024 (03.06.2024)
VIII-2-1 (iv)		an assignment from NOVARTIS PHARMA AG to NOVARTIS AG, dated 06 June 2024 (06.06.2024)

PCT

(Original in Electronic Form)

VIII-2-1 (iv)		an assignment from EHARA, Takeru to PEPTIDREAM INC. (ALSO KNOWN AS PEPTIDREAM K.K.), dated 19 June 2024 (19.06.2024)
VIII-2-1 (iv)		an assignment from MIZUKOSHI, Yoshihide to PEPTIDREAM INC. (ALSO KNOWN AS PEPTIDREAM K.K.), dated 19 June 2024 (19.06.2024)
VIII-2-1 (iv)		an assignment from PEPTIDREAM INC. (ALSO KNOWN AS PEPTIDREAM K.K.) to NOVARTIS PHARMA AG, dated 24 June 2024 (24.06.2024)
VIII-2-1 (iv)		an assignment from NOVARTIS PHARMA AG to NOVARTIS AG, dated 01 August 2024 (01.08.2024)
VIII-2-1 (iv)		an assignment from BONGARZONE, Salvatore to ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L., dated 24 July 2024 (24.07.2024)
VIII-2-1 (iv)		an assignment from CAMPORESE, Davide to ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L., dated 24 July 2024 (24.07.2024)
VIII-2-1 (iv)		an assignment from ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. to NOVARTIS AG, dated 01 August 2024 (01.08.2024)

PCT

TRADUCCIÓN - Original en formato
electrónico

VIII-2-1	Declaración: derecho a la solicitud y a la concesión de una patente Declaración con respecto al derecho del solicitante, a la fecha de la presentación internacional, a solicitar y a que se le conceda una patente (Normas 4.17(ii) y 51bis. 1(a)(ii)), en un caso en el que la declaración según la Norma 4.17(iv) no corresponde: Nombre	En relación con la presente solicitud internacional NOVARTIS AG tiene derecho a solicitar y a que se le conceda una patente en virtud de lo siguiente:
VI11-2-1 (iv)		una cesión de GOLOSOV, Andrei Alexandrovich a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., de fecha 04 de junio de 2024 (04.06.2024)
VI11-2-1 (iv)		una cesión de NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. a NOVARTIS AG, de fecha 16 de julio de 2024 (16.07.2024)
VI11-2-1 (iv)		una cesión de CLEMENTE, Gonçalo dos Santos a NOVARTIS PHARMA AG, de fecha 05 de junio de 2024 (05.06.2024)
VI11-2-1 (iv)		una cesión de FISCHER, Matteo a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de GROSCHE, Philipp a NOVARTIS PHARMA AG, de fecha 06 de junio de 2024 (06.06.2024)
VI11-2-1 (iv)		una cesión de HOLZER, Philipp a NOVARTIS PHARMA AG, de fecha 06 de junio de 2024 (06.06.2024)
VI11-2-1 (iv)		una cesión de KARPOV, Alexei a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de LACAUD-BAUMLIN, Marion a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de LEDER, Lukas a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de MALO, Rafael Bermeo a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de MARZINZIK, Andreas a NOVARTIS PHARMA AG, de fecha 05 de junio de 2024 (05.06.2024)
VI11-2-1 (iv)		una cesión de MUNSCH, Charlie a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de RESCHKE, Markus Oliver a NOVARTIS PHARMA AG, de fecha 06 de junio de 2024 (06.06.2024)
VI11-2-1 (iv)		una cesión de SELLNER, Holger a NOVARTIS PHARMA AG, de fecha 05 de junio de 2024 (05.06.2024)
VI11-2-1 (iv)		una cesión de STACHYRA, Therese-Marie a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de NOVARTIS PHARMA AG a NOVARTIS AG, de fecha 06 de junio de 2024 (06.06.2024)
VI11-2-1 (iv)		una cesión de EHARA, Takeru a PEPTIDREAM INC. (TAMBIÉN CONOCIDO COMO PEPTIDREAM K.K.), de fecha 19 de junio de 2024 (19.06.2024)
VI11-2-1 (iv)		una cesión de MIZUKOSHI, Yoshihide a PEPTIDREAM INC. (TAMBIÉN CONOCIDO COMO PEPTIDREAM K.K.), de fecha 19 de junio de 2024 (19.06.2024)

PCT

TRADUCCIÓN - Original en formato
electrónico

VI11-2-1 (iv)		una cesión de PEPTIDREAM INC. (TAMBIÉN CONOCIDO COMO PEPTIDREAM K.K.) a NOVARTIS PHARMA AG, de fecha 24 de junio de 2024 (24.06.2024)
VI11-2-1 (iv)		una cesión de NOVARTIS PHARMA AG a NOVARTIS AG, de fecha 01 de agosto de 2024 (01.08.2024)
VI11-2-1 (iv)		una cesión de BONGARZONE, Salvatore a ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L., de fecha 24 de julio de 2024 (24.07.2024)
VI11-2-1 (iv)		una cesión de CAMPORESE, Davide a ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L., de fecha 24 de julio de 2024 (24.07.2024)
VI11-2-1 (iv)		una cesión de ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. a NOVARTIS AG, de fecha 01 de agosto de 2024 (01.08.2024)
VI11-2-1 (iv)		una cesión de GOLOSOV, Andrei Alexandrovich a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., de fecha 04 de junio de 2024 (04.06.2024)
VI11-2-1 (iv)		una cesión de NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. a NOVARTIS AG, de fecha 16 de julio de 2024 (16.07.2024)
VI11-2-1 (iv)		una cesión de CLEMENTE, Gonçalo dos Santos a NOVARTIS PHARMA AG, de fecha 05 de junio de 2024 (05.06.2024)
VI11-2-1 (iv)		una cesión de FISCHER, Matteo a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de GROSCHE, Philipp a NOVARTIS PHARMA AG, de fecha 06 de junio de 2024 (06.06.2024)
VI11-2-1 (iv)		una cesión de HOLZER, Philipp a NOVARTIS PHARMA AG, de fecha 06 de junio de 2024 (06.06.2024)
VI11-2-1 (iv)		una cesión de KARPOV, Alexei a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de LACAUD-BAUMLIN, Marion a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de LEDER, Lukas a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de MALO, Rafael Bermeo a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de MARZINZIK, Andreas a NOVARTIS PHARMA AG, de fecha 05 de junio de 2024 (05.06.2024)
VI11-2-1 (iv)		una cesión de MUNSCH, Charlie a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de RESCHKE, Markus Oliver a NOVARTIS PHARMA AG, de fecha 06 de junio de 2024 (06.06.2024)
VI11-2-1 (iv)		una cesión de SELLNER, Holger a NOVARTIS PHARMA AG, de fecha 05 de junio de 2024 (05.06.2024)
VI11-2-1 (iv)		una cesión de STACHYRA, Therese-Marie a NOVARTIS PHARMA AG, de fecha 03 de junio de 2024 (03.06.2024)
VI11-2-1 (iv)		una cesión de NOVARTIS PHARMA AG a NOVARTIS AG, de fecha 06 de junio de 2024 (06.06.2024)

PCT

TRADUCCIÓN - Original en formato
electrónico

VI11-2-1 (iv)		una cesión de EHARA, Takeru a PEPTIDREAM INC. (TAMBIÉN CONOCIDO COMO PEPTIDREAM K.K.), de fecha 19 de junio de 2024 (19.06.2024)
VI11-2-1 (iv)		una cesión de MIZUKOSHI, Yoshihide a PEPTIDREAM INC. (TAMBIÉN CONOCIDO COMO PEPTIDREAM K.K.), de fecha 19 de junio de 2024 (19.06.2024)
VI11-2-1 (iv)		una cesión de PEPTIDREAM INC. (TAMBIÉN CONOCIDO COMO PEPTIDREAM K.K.) a NOVARTIS PHARMA AG, de fecha 24 de junio de 2024 (24.06.2024)
VI11-2-1 (iv)		una cesión de NOVARTIS PHARMA AG a NOVARTIS AG, de fecha 01 de agosto de 2024 (01.08.2024)
VI11-2-1 (iv)		una cesión de BONGARZONE, Salvatore a ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L., de fecha 24 de julio de 2024 (24.07.2024)
VI11-2-1 (iv)		una cesión de CAMPORESE, Davide a ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L., de fecha 24 de julio de 2024 (24.07.2024)
VI11-2-1 (iv)		una cesión de ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. a NOVARTIS AG, de fecha 01 de agosto de 2024 (01.08.2024)

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Salvatore BONGARZONE	citizen of Italy	ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. Via dell'industria Prima Traversa, 86077 Pozzilli (ISERNIA) Italy
Davide CAMPORESE	citizen of Italy	ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. Via dell'industria Prima Traversa, 86077 Pozzilli (ISERNIA) Italy

(hereinafter "Inventor(s)"),

and **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.**, Via dell'industria Prima Traversa, 86077, Pozzilli (ISERNIA), Italy, a company organized under the laws of Italy.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on August 15, 2023 and accorded Application Number 63/519,599;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Italy.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 24 day of JULY, 2024.

Salvatore Bongarzone
Salvatore BONGARZONE

Witness: Marco Trucco

Printed Name: MARCO TRUCCO

City, State and Country: VERCELLI, ITALY

Witness: Elena Castaldi

Printed Name: ELENA CASTALDI

City, State and Country: IVREA, TORINO, ITALY

Executed this _____ day of _____, 20____.

Davide CAMPORESE

Witness: _____
Printed Name:
City, State and Country:

Witness: _____
Printed Name:
City, State and Country:

Executed this 1 day of Aug., 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]

Printed Name: Sansun Yeh
Authorized Signatory

Witness: [Signature]

Printed Name:
City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov

Printed Name:
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

Executed this 1 day of August, 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]

Printed Name: Tim Wittkowski
Authorized Signatory

Witness: [Signature]

Printed Name:
City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov

Printed Name:
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Salvatore BONGARZONE	citizen of Italy	ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. Via dell'industria Prima Traversa, 86077 Pozzilli (ISERNIA) Italy
Davide CAMPORESE	citizen of Italy	ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. Via dell'industria Prima Traversa, 86077 Pozzilli (ISERNIA) Italy

(hereinafter "Inventor(s)"),

and **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.**, Via dell'industria Prima Traversa, 86077, Pozzilli (ISERNIA), Italy, a company organized under the laws of Italy.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on August 15, 2023 and accorded Application Number 63/519,599;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Italy.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____, 20____.

Salvatore BONGARZONE

Witness: _____
Printed Name:
City, State and Country:

Witness: _____
Printed Name:
City, State and Country:

Executed this 29 day of JULY, 2024.


Davide CAMPORESE

Witness: 
Printed Name: VUAUDET Carole

City, State and Country: 48 RUE LOUIS RICHARD
01630 SAINT-GENIS-POUILLY
FRANCE

Witness: 
Printed Name: VUAUDET Patrick

City, State and Country: 48 rue Louis Richard
01 630 St Genis Pouilly
FRANCE

Executed this 1 day of Aug., 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]
Printed Name: Sansun Yeh
Authorized Signatory

Witness: [Signature]
Printed Name: _____
City, State and Country: _____

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov
Printed Name: _____
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

Executed this 1 day of August, 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY Timothy Witkowski
Printed Name: Timothy Witkowski
Authorized Signatory

Witness: [Signature]
Printed Name: _____
City, State and Country: _____

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov
Printed Name: _____
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.**, whose address is Via dell'industria Prima Traversa, 86077, Pozzilli (ISERNIA), Italy; a company organized under the laws of **Italy** and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** confirms that **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** has sold, assigned, and transferred, and does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to;

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on August 15, 2023 and accorded Application Number 63/519,599;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.**, if this sale, assignment and transfer had not been made.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within

the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 1 day of August, 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]
Printed Name: Sansun Yeh
Authorized Signatory

Witness: [Signature]
Printed Name:
City, State and Country:

Lori A. Czerwinka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov
Printed Name:
City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

Executed this 1 day of August, 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]
Printed Name: Timothy Witkowski
Authorized Signatory

Witness: [Signature]
Printed Name:
City, State and Country:

Lori A. Czerwinka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov
Printed Name:
City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

Executed this 1st day of August, 2024.

NOVARTIS AG

BY

Printed Name:

Authorized Signatory

Tara M. Melanson
Authorized Signatory

Witness:

Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

NOVARTIS AG

BY

Printed Name:

Authorized Signatory

Laurie Lawrence

Witness:

Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Andrei Alexandrovich Golosov	citizen of United States of America	Novartis Institutes for Biomedical Research, Inc. 250 Massachusetts Avenue, Cambridge, MA 02139, USA
---------------------------------	--	---

(hereinafter "Inventor(s)"),

and **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States of America, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on August 15, 2023 and accorded Application Number 63/519,599;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the

right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this June day of 4th, 2024.

(Andrei A. Golosov)
Andrei Alexandrovich Golosov

Witness: Lori A. Czerwinka
Printed Name: Lori A. Czerwinka
City, State and Country: Cambridge, MA, USA

Witness: Gaby Martinez
Printed Name: Gaby Martinez
City, State and Country: Cambridge, MA, USA

Executed this 16th day of July, 20 24 .

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

BY Susan M Dillon
Printed Name: Susan M. Dillon
Authorized Signatory

Witness: Veronica Romanov
Printed Name:
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Lori A. Czerwonka
Printed Name:
City, State and Country: **Lori A. Czerwonka**
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Gonçalo Dos Santos Clemente	citizen of Portugal	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Matteo Fischer	citizen of Switzerland	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Philipp Grosche	citizen of Germany	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Philipp Holzer	citizen of Switzerland	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Alexei Karpov	citizen of Russian Federation	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Marion Lacaud-Baumlin	citizen of France	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Lukas Leder	citizen of Switzerland	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Rafael Bermeo Malo	citizen of Ecuador	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Andreas Marzinzik	citizen of Germany	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Charlie Munsch	citizen of France	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland

Markus Oliver Reschke	citizen of Austria	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Holger Sellner	citizen of Germany	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Therese-Marie Stachyra	citizen of France	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland

(hereinafter "Inventor(s)"),

and **NOVARTIS PHARMA AG**, Lichtstrasse 35, 4056 Basel, Switzerland, a company organized under the laws of Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS PHARMA AG** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **NOVARTIS PHARMA AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on August 15, 2023 and accorded Application Number 63/519,599;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the

right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 5th day of June, 2024.

Gonçalo Dos Santos Clemente
Gonçalo Dos Santos Clemente

Witness: C. Stark
Printed Name: **Cornelia Stark**
City, State and Country: **Lichtstrasse 35**
4056 Basel
Switzerland

Witness: Laura Keller
Printed Name: **Laura Keller**
City, State and Country: **Lichtstrasse 35**
4056 Basel
Switzerland

Executed this 3. day of June, 2024.

Matteo Fischer
Matteo Fischer

Witness: C. Stark

Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: [Signature]

Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 6 day of June, 2024.

Philipp Grosche
Philipp Grosche

Witness: C. Stark

Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: [Signature]

Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 6th day of June, 2024.

Philipp Holzner
Philipp Holzner

Witness:

C. Stark

Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness:

[Signature]

Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 3rd day of June, 2024.

Alexei Karpov
Alexei Karpov

Witness:

C. Stark

Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness:

[Signature]

Printed Name:
City, State and Country:


Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 3rd day of June, 2024.



Marion Lacaud-Baumlin

Witness:



Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland


Witness:



Printed Name:
City, State and Country:


Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 03 day of June, 2024.



Lukas Leder

Witness:



Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness:



Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 3rd day of June, 20 24.

Rafael Bermeo Malo
Rafael Bermeo Malo

Witness: C. Stark
Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: [Signature]
Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 5th day of June, 20 24.
Andreas Marzinzik
Andreas Marzinzik

Witness: C. Stark
Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: [Signature]
Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 3rd day of June, 2024.




Charlie Munsch

Witness: C. Stark

Printed Name:
City, State and Country:


Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: 

Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 6th day of June, 2024.



Markus Oliver Reschke

Witness: C. Stark

Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: 

Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 5 day of June, 2024.

H. Seller
Holger Seller

Witness: C. Stark
Printed Name: **Cornelia Stark**
City, State and Country: **Lichtstrasse 35**
4056 Basel
Switzerland

Witness: [Signature]
Printed Name: **Laura Keller**
City, State and Country: **Lichtstrasse 35**
4056 Basel
Switzerland

Executed this 3 day of June, 2024.


[Signature]
Therese-Marie Stachyra


Witness: C. Stark
Printed Name: **Cornelia Stark**
City, State and Country: **Lichtstrasse 35**
4056 Basel
Switzerland

Witness: [Signature]
Printed Name: **Laura Keller**
City, State and Country: **Lichtstrasse 35**
4056 Basel
Switzerland

Executed this 06 day of JUNE, 2024.


NOVARTIS PHARMA AG


BY 
Printed Name: _____
Authorized Signatory **SUDESHNA PATEKAR**
AUTHORIZED SIGNATORY

Witness: 
Printed Name: _____
City, State and Country: **Cornelia Stark**
Lichtstrasse 35
4056 Basel
Switzerland

Witness: 
Printed Name: _____
City, State and Country: **Laura Keller**
Lichtstrasse 35
4056 Basel
Switzerland

NOVARTIS PHARMA AG

BY  **Dieter Kuhn**
Printed Name: _____
Authorized Signatory **Authorized Signatory**

Witness: 
Printed Name: _____
City, State and Country: **Cornelia Stark**
Lichtstrasse 35
4056 Basel
Switzerland

Witness: 
Printed Name: _____
City, State and Country: **Laura Keller**
Lichtstrasse 35
4056 Basel
Switzerland

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Takeru EHARA	Citizen of Japan	PeptiDream Inc., 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa JAPAN 210-0821
Yoshihide MIZUKOSHI	Citizen of Japan	PeptiDream Inc., 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa JAPAN 210-0821

(hereinafter "Inventor(s)"),

and **PEPTIDREAM INC.** (also known as **PEPTIDREAM K.K.**), 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa JAPAN 210-0821, a company organized under the laws of Japan.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **PEPTIDREAM INC.** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **PEPTIDREAM INC.** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on August 15, 2023 and accorded Application Number 63/519,599;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 19 day of June, 2024.

T. Ehara
Takeru EHARA

Witness: Hitomi Hamamoto
Printed Name: HITOMI HAMAMOTO
City, State and Country: Kawasaki, Kanagawa, Japan

Witness: S. Yokota
Printed Name: Shunichi YOKOTA
City, State and Country: Kawasaki, Kanagawa, Japan

Executed this 19 day of June, 2024.

Y. Mizukoshi
Yoshihide MIZUKOSHI

Witness: Hitomi Hamamoto
Printed Name: HITOMI HAMAMOTO
City, State and Country: Kawasaki, Kanagawa, Japan

Witness: S. Yokota
Printed Name: Shunichi YOKOTA
City, State and Country: Kawasaki, Kanagawa, Japan

Executed this 24 day of June, 2024.

PEPTIDREAM INC.

BY Patrick C. Reid
Printed Name: Patrick C. REID
Authorized Signatory

Witness: Hitomi Hamamoto
Printed Name: Hitomi HAMAMOTO
City, State and Country: Kawasaki, Kanagawa, Japan

Witness: Shunichi Yokota
Printed Name: Shunichi YOKOTA
City, State and Country: kawasaki, kanagawa, Japan

ASSIGNMENT

This Assignment Agreement is entered into by and between **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States of America; a company organized under the laws of Delaware; and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** confirms that **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** has sold, assigned, and transferred, and does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on August 15, 2023 and accorded Application Number 63/519,599;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, if this sale, assignment and transfer had not been made.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within

the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 16th day of July, 20 24.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

BY Susan M Dillon
 Printed Name: Susan M. Dillon
 Authorized Signatory

Witness: Veronica Romanov
 Printed Name:
 City, State and Country: **Veronica Romanov**
 250 Massachusetts Avenue
 Cambridge, MA 02139 US

Witness: Lori A. Czerwonka
 Printed Name: **Lori A. Czerwonka**
 City, State and Country: **250 Massachusetts Avenue**
Cambridge, MA 02139 US

Executed this 16th day of July, 2024.

NOVARTIS AG

BY Tara M. Melanson

Printed Name:

Authorized Signatory

Tara M. Melanson
Authorized Signatory

Witness: Veronica Romanov

Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Lori A. Czerwonka

Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

NOVARTIS AG

BY Kathleen M. Drury

Printed Name:

Authorized Signatory

KATHLEEN M DRURY

Witness: Veronica Romanov

Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Lori A. Czerwonka

Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between **NOVARTIS PHARMA AG**, Lichtstrasse 35, 4056 Basel, Switzerland, a company organized under the laws of Switzerland; and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS PHARMA AG** confirms that **NOVARTIS PHARMA AG** has sold, assigned, and transferred, and does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office August 15, 2023 and accorded Application Number 63/519,599;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national

stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **NOVARTIS PHARMA AG** if this sale, assignment and transfer had not been made.

NOVARTIS PHARMA AG hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. **NOVARTIS PHARMA AG** also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

NOVARTIS PHARMA AG hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 1 day of Aug, 2024.

NOVARTIS PHARMA AG

BY [Signature]
 Printed Name: _____
 Authorized Signatory
Jeremy Reich
 Authorized Signatory

Witness: [Signature]
 Printed Name: _____
 City, State and Country: _____
Lori A. Czerwonka
 250 Massachusetts Avenue
 Cambridge, MA 02139 US

Witness: Veronica Romanov
 Printed Name: _____
 City, State and Country: **Veronica Romanov**
 250 Massachusetts Avenue
 Cambridge, MA 02139 US

NOVARTIS PHARMA AG

BY [Signature]
 Printed Name: Victoria L Smith
 Authorized Signatory

Witness: [Signature]
 Printed Name: _____
 City, State and Country: _____
Lori A. Czerwonka
 250 Massachusetts Avenue
 Cambridge, MA 02139 US

Witness: Veronica Romanov
 Printed Name: _____
 City, State and Country: **Veronica Romanov**
 250 Massachusetts Avenue
 Cambridge, MA 02139 US

Executed this 1st day of August, 2024.

NOVARTIS AG

BY

Tara M. Melanson
Printed Name:
Authorized Signatory

Tara M. Melanson
Authorized Signatory

Witness:

Lori A. Czerwonka
Printed Name:
City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Veronica Romanov
Printed Name:
City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

NOVARTIS AG

BY

Laurie Lawrence
Printed Name: LAURIE LAWRENCE
Authorized Signatory

Witness:

Lori A. Czerwonka
Printed Name:
City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Veronica Romanov
Printed Name:
City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between **PEPTIDREAM INC.** (also known as **PEPTIDREAM K.K.**), whose address is 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa JAPAN 210-0821; a company organized under the laws of Japan and **NOVARTIS PHARMA AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **PEPTIDREAM INC.** confirms that **PEPTIDREAM INC.** has sold, assigned, and transferred, and does hereby sell, assign and transfer to **NOVARTIS PHARMA AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to;

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on August 15, 2023 and accorded Application Number 63/519,599;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national

stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **PEPTIDREAM INC.** if this sale, assignment and transfer had not been made.

PEPTIDREAM INC. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. **PEPTIDREAM INC.** also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

PEPTIDREAM INC. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 24 day of June, 20224.

PEPTIDREAM INC.

BY Patrick C. Reid
Printed Name: Patrick C. REID
Authorized Signatory

Witness: Hitomi Hamamoto
Printed Name: Hitomi HAMAMOTO
City, State and Country: Kawasaki, Kanagawa, Japan

Witness: S. Yokota
Printed Name: Shunichi YOKOTA
City, State and Country: Kawasaki, Kanagawa Japan

Executed this 1 day of August, 2024.


NOVARTIS PHARMA AG

BY 

Printed Name:

Authorized Signatory

Jeremy Reich
Authorized Signatory

Witness: 

Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov

Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

NOVARTIS PHARMA AG

BY Vito L Smith

Printed Name:

Authorized Signatory

Victory L Smith

Witness: 

Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov

Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.**, whose address is Via dell'industria Prima Traversa, 86077, Pozzilli (ISERNIA), Italy; a company organized under the laws of **Italy** and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** confirms that **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** has sold, assigned, and transferred, and does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to;

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on May 21, 2024 and accorded Application Number 63/650,139;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.**, if this sale, assignment and transfer had not been made.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within

the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 1 day of August, 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]
Printed Name: Sansun Yeh
Authorized Signatory

Witness: [Signature]
Printed Name: _____
City, State and Country: **Lori A. Czerwonka**
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov
Printed Name: _____
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

Executed this 1 day of August, 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]
Printed Name: Timothy Witkowski
Authorized Signatory

Witness: [Signature]
Printed Name: _____
City, State and Country: **Lori A. Czerwonka**
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov
Printed Name: _____
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

Executed this 1st day of August, 2024.

NOVARTIS AG

BY Tara M. Melanson
 Printed Name: Tara M. Melanson
 Authorized Signatory

Tara M. Melanson
 Authorized Signatory

Witness: Lori A. Czerwonka
 Printed Name: Lori A. Czerwonka
 City, State and Country: 250 Massachusetts Avenue
 Cambridge, MA 02139 US

Witness: Veronica Romanov
 Printed Name: Veronica Romanov
 City, State and Country: 250 Massachusetts Avenue
 Cambridge, MA 02139 US

NOVARTIS AG

BY Laurie Lawrence
 Printed Name: LAURIE LAWRENCE
 Authorized Signatory

Witness: Lori A. Czerwonka
 Printed Name: Lori A. Czerwonka
 City, State and Country: 250 Massachusetts Avenue
 Cambridge, MA 02139 US

Witness: Veronica Romanov
 Printed Name: Veronica Romanov
 City, State and Country: 250 Massachusetts Avenue
 Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Salvatore BONGARZONE	citizen of Italy	ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. Via dell'industria Prima Traversa, 86077 Pozzilli (ISERNIA) Italy
Davide CAMPORESE	citizen of Italy	ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. Via dell'industria Prima Traversa, 86077 Pozzilli (ISERNIA) Italy

(hereinafter "Inventor(s)"),

and **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.**, Via dell'industria Prima Traversa, 86077, Pozzilli (ISERNIA), Italy, a company organized under the laws of Italy.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on May 21, 2024 and accorded Application Number 63/650,139;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Italy.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 24 day of JULY, 2024.

Salvatore Bongarzone
Salvatore BONGARZONE

Witness: Marco Trucco

Printed Name: MARCO TRUCCO

City, State and Country: VERCELLI, ITALY

Witness: Elena Cascardi

Printed Name: ELENA CASCARDI

City, State and Country: IVERA, TORINO, ITALY

Executed this _____ day of _____, 20_____.

Davide CAMPORESE

Witness: _____
Printed Name:
City, State and Country:

Witness: _____
Printed Name:
City, State and Country:

Executed this 1 day of Aug., 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]
Printed Name: Sansun Yeh
Authorized Signatory

Witness: [Signature]
Printed Name: _____
City, State and Country: _____

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov
Printed Name: _____
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

Executed this 1 day of August, 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]
Printed Name: Timothy Witkowski
Authorized Signatory

Witness: [Signature]
Printed Name: _____
City, State and Country: _____

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Veronica Romanov
Printed Name: _____
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Salvatore BONGARZONE	citizen of Italy	ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. Via dell'industria Prima Traversa, 86077 Pozzilli (ISERNIA) Italy
Davide CAMPORESE	citizen of Italy	ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. Via dell'industria Prima Traversa, 86077 Pozzilli (ISERNIA) Italy

(hereinafter "Inventor(s)"),

and **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.**, Via dell'industria Prima Traversa, 86077, Pozzilli (ISERNIA), Italy, a company organized under the laws of Italy.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on May 21, 2024 and accorded Application Number 63/650,139;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Italy.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____, 20____.

Salvatore BONGARZONE

Witness: _____

Printed Name:

City, State and Country:

Witness: _____


Printed Name:

City, State and Country:


Executed this 24 day of JULY, 2024.



Davide CAMPORESE

Witness: 

Printed Name: VUALLET CAROLE
City, State and Country: 48 RUE LOUIS RICHARD
01630 SAINT-GENIS-POUILLY
FRANCE

Witness: 

Printed Name: VUALLET Patrick
City, State and Country: 48 rue Louis Richard
01630 St Genis Pouilly
FRANCE

Executed this 1 day of Aug., 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]
Printed Name: Sansun Yeh
Authorized Signatory

Witness: [Signature] **Lori A. Czerwonka**
Printed Name: 250 Massachusetts Avenue
City, State and Country: Cambridge, MA 02139 US

Witness: Veronica Romanov
Printed Name:
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

Executed this 1 day of August, 2024.

ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L.

BY [Signature]
Printed Name: Timothy Witkowski
Authorized Signatory

Witness: [Signature] **Lori A. Czerwonka**
Printed Name: 250 Massachusetts Avenue
City, State and Country: Cambridge, MA 02139 US

Witness: Veronica Romanov
Printed Name:
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Andrei Alexandrovich Golosov	citizen of United States of America	Novartis Institutes for Biomedical Research, Inc. 250 Massachusetts Avenue, Cambridge, MA 02139, USA
---------------------------------	--	---

(hereinafter "Inventor(s)"),

and **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States of America, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on May 21, 2024 and accorded Application Number 63/650,139;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the

right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this June day of 4th, 2024.

(Andrei A Golosov)
Andrei Alexandrovich Golosov

Witness: (Lori A. Czerwonka)

Printed Name: Lori A. Czerwonka

City, State and Country: Cambridge, MA, USA

Witness: Galy Martinez

Printed Name: Galy Martinez

City, State and Country: Cambridge, MA, USA

Executed this 16th day of July, 2024.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

BY Susan M Dillon
Printed Name: Susan M. Dillon
Authorized Signatory

Witness: Veronica Romanov
Printed Name:
City, State and Country: **Veronica Romanov**
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness: Lori A. Czerwonka
Printed Name:
City, State and Country: **Lori A. Czerwonka**
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Gonalo Dos Santos Clemente	citizen of Portugal	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Matteo Fischer	citizen of Switzerland	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Philipp Grosche	citizen of Germany	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Philipp Holzer	citizen of Switzerland	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Alexei Karpov	citizen of Russian Federation	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Marion Lacaud-Baumlin	citizen of France	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Lukas Leder	citizen of Switzerland	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Rafael Bermeo Malo	citizen of Ecuador	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Andreas Marzinzik	citizen of Germany	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Charlie Munsch	citizen of France	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland

Markus Oliver Reschke	citizen of Austria	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Holger Sellner	citizen of Germany	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland
Therese-Marie Stachyra	citizen of France	Novartis Pharma AG Lichtstrasse 35, 4056 Basel, Switzerland

(hereinafter "Inventor(s)"),

and **NOVARTIS PHARMA AG**, Lichtstrasse 35, 4056 Basel, Switzerland, a company organized under the laws of Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS PHARMA AG** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **NOVARTIS PHARMA AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on May 21, 2024 and accorded Application Number 63/650,139;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the

right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 5th day of June, 2024.

Gonçalo dos Santos Clemente
Gonçalo Dos Santos Clemente

Witness:

C. Stark

Printed Name:

City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness:

[Signature]

Printed Name:

City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 3 day of June, 2024.

M. Fischer

Matteo Fischer

Witness: C. Stark

Printed Name:

City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: [Signature]

Printed Name:

City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 6 day of June, 2024.

P. Grosche

Philipp Grosche

Witness: C. Stark

Printed Name:

City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: [Signature]

Printed Name:

City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 6th day of June, 2024.

Philipp Holzer
Philipp Holzer

Witness:

C. Stark

Printed Name:

City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness:

[Signature]

Printed Name:

City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 3rd day of June, 2024.

Alexei Karpov
Alexei Karpov

Witness:

C. Stark

Printed Name:

City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness:

[Signature]

Printed Name:

City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 30 day of June, 2024.

[Signature]
Marion Lacard-Baumlin

Witness: C. Stark
Printed Name: **Cornelia Stark**
City, State and Country: **Lichtstrasse 35**
4056 Basel
Switzerland

Witness: [Signature]
Printed Name: **Laura Keller**
City, State and Country: **Lichtstrasse 35**
4056 Basel
Switzerland

Executed this 03 day of June, 2024.

[Signature]
Lukas Leder

Witness: C. Stark
Printed Name: **Cornelia Stark**
City, State and Country: **Lichtstrasse 35**
4056 Basel
Switzerland

Witness: [Signature]
Printed Name: **Laura Keller**
City, State and Country: **Lichtstrasse 35**
4056 Basel
Switzerland

Executed this 3rd day of June, 2024.

Rafael Bermeo Malo
Rafael Bermeo Malo

Witness: C. Stark
Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: Laura Keller
Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 5th day of June, 2024.
Andreas Marzinzik
Andreas Marzinzik

Witness: C. Stark
Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: Laura Keller
Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 3rd day of June, 2024.


Charlie Munsch

Witness:



Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland


Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Witness:



Printed Name:
City, State and Country:

Executed this 6th day of June, 2024.


Markus Oliver Reschke

Witness:



Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness:



Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 5 day of June, 2024.

H. Sellner
Holger Sellner

Witness: C. Stark

Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland

Witness: [Signature]

Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 3 day of June, 2024.

[Signature]
Therese-Marie Stachyra

Witness: C. Stark

Printed Name:
City, State and Country:

Cornelia Stark
Lichtstrasse 35
4056 Basel
Switzerland


Witness: [Signature]

Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 06 day of JUNE, 2024.


NOVARTIS PHARMA AG


BY 
Printed Name: _____
Authorized Signatory **SUDESHNA PATEKAR**
AUTHORIZED SIGNATORY

Witness:  **Cornelia Stark**
Printed Name: Lichtstrasse 35
City, State and Country: 4056 Basel
Switzerland

Witness:  **Laura Keller**
Printed Name: Lichtstrasse 35
City, State and Country: 4056 Basel
Switzerland

NOVARTIS PHARMA AG

BY  **Dieter Kuhn**
Printed Name: _____
Authorized Signatory **Authorized Signatory**

Witness:  **Cornelia Stark**
Printed Name: Lichtstrasse 35
City, State and Country: 4056 Basel
Switzerland

Witness:  **Laura Keller**
Printed Name: Lichtstrasse 35
City, State and Country: 4056 Basel
Switzerland

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Takeru EHARA	Citizen of Japan	PeptiDream Inc., 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa JAPAN 210-0821
Yoshihide MIZUKOSHI	Citizen of Japan	PeptiDream Inc., 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa JAPAN 210-0821

(hereinafter "Inventor(s)"),

and **PEPTIDREAM INC.** (also known as **PEPTIDREAM K.K.**), 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa JAPAN 210-0821, a company organized under the laws of Japan.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **PEPTIDREAM INC.** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **PEPTIDREAM INC.** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on May 21, 2024 and accorded Application Number 63/650,139;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 19 day of June, 2024.

T. Ehara
Takeru EHARA

Witness: Hitomi Hamamoto
Printed Name: Hitomi HAMAMOTO
City, State and Country: Kawasaki, Kanagawa, Japan

Witness: S. Yokota
Printed Name: Shunichi YOKOTA
City, State and Country: Kawasaki, Kanagawa, Japan

Executed this 19 day of June, 2024.

Y. Mizukoshi
Yoshihide MIZUKOSHI

Witness: Hitomi Hamamoto
Printed Name: Hitomi HAMAMOTO
City, State and Country: Kawasaki, Kanagawa, Japan

Witness: S. Yokota
Printed Name: Shunichi YOKOTA
City, State and Country: Kawasaki, Kanagawa, Japan

Executed this 24 day of June, 2024.

PEPTIDREAM INC.

BY Patrick C. Reid
Printed Name: Patrick C. REID
Authorized Signatory

Witness: Hitomi Hamamoto
Printed Name: Hitomi HAMAMOTO
City, State and Country: Kawasaki, Kanagawa, Japan

Witness: Shunichi Yokota
Printed Name: Shunichi YOKOTA
City, State and Country: Kawasaki, Kanagawa, Japan

ASSIGNMENT

This Assignment Agreement is entered into by and between **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States of America; a company organized under the laws of Delaware; and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** confirms that **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** has sold, assigned, and transferred, and does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on May 21, 2024 and accorded Application Number 63/650,139;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, if this sale, assignment and transfer had not been made.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within

the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 16th day of July, 2024.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

BY Susan M. Dillon
 Printed Name: Susan M. Dillon
 Authorized Signatory

Witness: Veronica Romanov
 Printed Name:
 City, State and Country: **Veronica Romanov**
 250 Massachusetts Avenue
 Cambridge, MA 02139 US

Witness: Lori A. Czerwonka
 Printed Name:
 City, State and Country: **Lori A. Czerwonka**
 250 Massachusetts Avenue
 Cambridge, MA 02139 US

Executed this 16th day of July, 2024.

NOVARTIS AG

BY

Printed Name:

Authorized Signatory

Tara M. Melanson
Authorized Signatory

Witness:

Veronica Romanov

Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Lori A. Czerwonka

Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

NOVARTIS AG

BY

Kathleen M. Drury
Printed Name: KATHLEEN M. DRURY
Authorized Signatory

Witness:

Veronica Romanov

Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Lori A. Czerwonka

Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between **NOVARTIS PHARMA AG**, Lichtstrasse 35, 4056 Basel, Switzerland, a company organized under the laws of Switzerland; and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS PHARMA AG** confirms that **NOVARTIS PHARMA AG** has sold, assigned, and transferred, and does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office May 21, 2024 and accorded Application Number 63/650,139;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national

stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **NOVARTIS PHARMA AG** if this sale, assignment and transfer had not been made.

NOVARTIS PHARMA AG hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. **NOVARTIS PHARMA AG** also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

NOVARTIS PHARMA AG hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 1 day of Aug, 2024.

NOVARTIS PHARMA AG

BY

[Signature]
Printed Name:

Authorized Signatory

Jeremy Reich
Authorized Signatory

Witness:

[Signature]
Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Veronica Romanov
Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

NOVARTIS PHARMA AG

BY

[Signature]
Printed Name:

Authorized Signatory

Witness:

[Signature]
Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Veronica Romanov
Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

Executed this 1st day of August, 2024.

NOVARTIS AG

BY

Printed Name:

Authorized Signatory

Tara M. Melanson
Authorized Signatory

Witness:

Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

NOVARTIS AG

BY

Printed Name:

Authorized Signatory

Witness:

Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between **PEPTIDREAM INC.** whose address is 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa JAPAN 210-0821; a company organized under the laws of Japan and **NOVARTIS PHARMA AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **PEPTIDREAM INC.** confirms that **PEPTIDREAM INC.** has sold, assigned, and transferred, and does hereby sell, assign and transfer to **NOVARTIS PHARMA AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to;

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

and filed in the United States Patent and Trademark Office on May 21, 2024 and accorded Application Number 63/650,139;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in

paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **PEPTIDREAM INC.** if this sale, assignment and transfer had not been made.

PEPTIDREAM INC. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. **PEPTIDREAM INC.** also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

PEPTIDREAM INC. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such

provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 24 day of June, 2024.

PEPTIDREAM INC.

BY *Patricia Reil*
Printed Name:
Authorized Signatory

Witness: *Hitomi Hamamoto*
Printed Name: Hitomi HAMAMOTO
City, State and Country: Kawasaki, Kanagawa, Japan

Witness: *Shunichi Yokota*
Printed Name: Shunichi YOKOTA
City, State and Country: Kawasaki, Kanagawa, Japan

Executed this 1 day of August, 2024.

NOVARTIS PHARMA AG

BY


Printed Name:

Authorized Signatory

Jeremy Reich
Authorized Signatory

Witness:


Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Veronica Romanov
Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US

NOVARTIS PHARMA AG

BY


Printed Name:

Authorized Signatory

Victoria L. Smith

Witness:


Printed Name:

City, State and Country:

Lori A. Czerwonka
250 Massachusetts Avenue
Cambridge, MA 02139 US

Witness:

Veronica Romanov
Printed Name:

City, State and Country:

Veronica Romanov
250 Massachusetts Avenue
Cambridge, MA 02139 US